ESK-001-023
12 evidence topics · 2 sources
Objective
Brief summary in the ClinicalTrials.gov record
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
“Study Start (Actual) 2025-04-23” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-08-01” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2025-08-01” (opens the source at this quote in a new tab)
“First Posted 2025-05-08” (opens the source at this quote in a new tab)
Start and completion dates estimated at registration, April 2025, superseded in December 2025
Sites in Florida in the ClinicalTrials.gov record
| Site | Quoted record |
|---|---|
| Florida | “Miami, Florida, United States, 33147” |
| Florida | “Miami Lakes, Florida, United States, 33014” |
| Florida | “Miami Lakes, Florida, United States, 33016” |
| Florida | “Orlando, Florida, United States, 32809” |
Recruitment and results status in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Overall status | “Completed” |
| Results | “No Results Posted” |
| Last update posted | “2025-12-10” |
Study design
Official title and design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Other study ID numbers | “ESK-001-023” |
| Conditions | “Renal Impairment” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Participant)” |
Eligibility criteria
Key inclusion and exclusion criteria in the ClinicalTrials.gov record
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using pharmacokinetic parameters and adverse event incidence as the primary endpoints
Primary and secondary outcome measures in the ClinicalTrials.gov record
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment in the ClinicalTrials.gov record
Enrollment estimated at registration, April 2025, superseded in December 2025
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
- No pharmacokinetic or adverse event results of the renal impairment study have been posted, and the report holds no published results; its ClinicalTrials.gov record reads “No Results Posted”.
- Only participants were masked, allocation was non-randomized, and each participant received a single dose with outcomes assessed over 48 hours.
- Enrollment was 16 participants, against 48 estimated at registration, at four sites in Florida; the record plans 8 participants each with mild, moderate, and severe renal impairment but does not report how many were enrolled in each group, and participants requiring dialysis were not eligible.